A Ras gene mutation is a common driver of follicular-pattern thyroid tumors. When a Ras gene (NRAS, HRAS, or KRAS) acquires a gain-of-function mutation, it keeps the Ras protein in an active state, pushing signaling through pathways like MAPK and PI3K. This promotes the follicular architecture and the kind of growth and invasion seen in follicular carcinoma. In contrast, mutations and rearrangements like BRAF V600E and RET/PTC are more characteristic of papillary thyroid carcinoma, not follicular. PIK3CA mutations can occur in thyroid cancers but are not the hallmark feature of follicular carcinoma, making Ras mutations the best-supported association.

Insulinoma is a pancreatic beta‑cell tumor that secretes insulin autonomously. Excess insulin lowers blood glucose by promoting glucose uptake into muscle and fat and by inhibiting hepatic glucose production, so it causes hypoglycemia. That’s why producing hypoglycemia is the correct description of its role. It does not raise glucose by secreting insulin, it does not secrete glucagon, and it does affect glucose homeostasis.

This question tests the organ triad most characteristic of MEN1. MEN1 predisposes to tumors in three endocrine glands: parathyroids, pituitary, and pancreatic islet cells. Among these, parathyroid involvement is the most common and often presents first as hyperparathyroidism from gland hyperplasia. Pituitary adenomas are also frequent, typically prolactin-secreting but can involve other pituitary hormones. Pancreatic neuroendocrine tumors arise from the islet cells, with gastrinomas, insulinomas, and other neuroendocrine tumors observed in MEN1. Other glands listed in the options—such as the thyroid or adrenal glands—are not the hallmark targets of MEN1 (distinct MEN syndromes involve those tissues). Hence, pituitary, pancreas, and parathyroid best fit the MEN1 pattern.

End-organ resistance to parathyroid hormone is the key idea. In pseudohypoparathyroidism, the parathyroid glands release plenty of hormone, but the kidneys and bones don’t respond due to a defect in PTH signaling. Because the target tissues don’t react, calcium stays low despite high PTH, and phosphate tends to be elevated since the kidney can’t excrete it effectively. The body keeps secreting more PTH in an attempt to raise calcium, so PTH remains high even though calcium remains low. This pattern—high PTH with hypocalcemia from receptor signaling failure—fits pseudohypoparathyroidism rather than other forms of hyperparathyroidism, where calcium levels would differ (primary hyperparathyroidism usually raises calcium; secondary hyperparathyroidism often has low or normal calcium with compensatory high PTH).